Who are MMRvaxpro's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Zostavax vaccine, varicella-5, Zoster Vaccine Live, Mumps vaccine, Yellow Fever 17DD Vaccine, Bacille Calmette-Guérin (BCG).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/mmrvaxpro.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

MMRvaxpro — Competitive Intelligence Brief

MMRvaxpro (MMRvaxpro) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Live attenuated vaccine. Area: Immunology / Infectious Disease.

marketed Live attenuated vaccine Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

MMRvaxpro (MMRvaxpro) — Rigshospitalet, Denmark. MMRvaxpro is a live attenuated vaccine that stimulates the immune system to produce antibodies and cellular immunity against measles, mumps, and rubella viruses.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
MMRvaxpro TARGET	MMRvaxpro	Rigshospitalet, Denmark	marketed	Live attenuated vaccine
Zostavax vaccine	Zostavax vaccine	Oklahoma Medical Research Foundation	marketed	Live attenuated vaccine	Varicella-zoster virus (VZV)
varicella-5	varicella-5	Changchun Keygen Biological Products Co., Ltd.	marketed	Live attenuated vaccine	Varicella-zoster virus
Zoster Vaccine Live	Zoster Vaccine Live	Merck Sharp & Dohme LLC	marketed	Live attenuated vaccine	Varicella-zoster virus (VZV)
Mumps vaccine	Mumps vaccine	Sinovac (Dalian) Vaccine Technology Co., Ltd.	marketed	Live attenuated vaccine	Mumps virus surface antigens
Yellow Fever 17DD Vaccine	Yellow Fever 17DD Vaccine	Centers for Disease Control and Prevention	marketed	live attenuated vaccine
Bacille Calmette-Guérin (BCG)	Bacille Calmette-Guérin (BCG)	TASK Applied Science	marketed	Live attenuated vaccine / Immunotherapy	Pattern recognition receptors (TLR2, TLR4, NOD2); non-specific immune activation

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Live attenuated vaccine class)

GlaxoSmithKline · 19 drugs in this class
Merck Sharp & Dohme LLC · 11 drugs in this class
Sanofi Pasteur, a Sanofi Company · 9 drugs in this class
PATH · 5 drugs in this class
Sanofi · 5 drugs in this class
Bandim Health Project · 5 drugs in this class
Centers for Disease Control and Prevention · 3 drugs in this class
International Centre for Diarrhoeal Disease Research, Bangladesh · 3 drugs in this class
Beijing Center for Disease Control and Prevention · 2 drugs in this class
Aga Khan University · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). MMRvaxpro — Competitive Intelligence Brief. https://druglandscape.com/ci/mmrvaxpro. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab